Home /

Latest news

January 16, 2026

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026...

January 12, 2026

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx AbbVie will commit $100 billion in U.S....

January 12, 2026

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/...

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

Press Kits

Our press kits are designed to provide journalists with a broad range of background information on our company.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Stay up to date on recent news, articles, and more.

News

Month Year

Get News Alerts by Email

November 18, 2024

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
November 14, 2024

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
November 11, 2024

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
November 07, 2024

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
- Photos 2
October 31, 2024

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
October 30, 2024

AbbVie Reports Third-Quarter 2024 Financial Results
October 29, 2024

SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
October 28, 2024

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
October 24, 2024

AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
October 18, 2024

BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
October 17, 2024

U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
October 16, 2024

Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
October 04, 2024

Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
October 02, 2024

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
- Photos 1
October 01, 2024

AbbVie to Host Third-Quarter 2024 Earnings Conference Call
September 27, 2024

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
September 26, 2024

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
September 25, 2024

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
September 24, 2024

Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
- Video 1
September 20, 2024

AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
September 11, 2024

Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
September 09, 2024

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
September 06, 2024

AbbVie Declares Quarterly Dividend
August 27, 2024

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
- Photos 1
August 27, 2024

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
- Photos 1

Show per page

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2024 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2024 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?